Luma buy fleshes out SpectraScience's cancer detection portfolio:
This article was originally published in Clinica
San Diego, California-based SpectraScience has expanded its reach in the cancer detection market with the acquisition of Luma Imaging, a developer of optical noninvasive cervical cancer diagnostic technology. Luma's FDA-approved cervical imaging system is designed as an easy-to-use adjunctive device to conventional colposcopy to improve the detection of cervical cancer. Clinical trials have shown that the product can detect over 25% more precancerous cells in the cervix than colposcopy alone. Luma's technology complements SpectraScience's WavSTAT system, which is also optics-based and noninvasive. The WavSTAT is approved for use in detecting precancer and cancer in the colon. SpectraScience is currently evaluating its technology for detecting precancers in the throat.
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.